Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
Related deals
DierenDokters has been acquired by VetPartners
DierenDokters, a leading group of fourteen veterinary clinics located across the Netherlands, has been acquired by VetPartners, a UK-based group of over 650 veterinary clinics and hospitals located across Europe. By partnering with VetPartners, DierenDokters welcomes a strong new shareholder that will help further enhance DierenDokters’ clinics’ service offering and allow the clinics to continue focusing on providing the best possible animal healthcare services.
Learn moreConnexicon Medical has been acquired by Advanced Medical Solutions PLC
Connexicon Medical Ltd has been sold to Advanced Medical Solutions PLC.
Learn moreTherapy Equipment has been acquired by ESAB Corporation
Owner Venture Managers has sold Therapy Equipment Ltd. to ESAB Corporation.
Learn more